Mike Bray

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Experimental therapy of filovirus infections
    Mike Bray
    Department of Viral Therapeutics, Virology Division, US Army Medical Research Institute of Infectious Diseases USAMRIID, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Antiviral Res 54:1-17. 2002
  2. ncbi request reprint Looking back at smallpox
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 38:882-9. 2004
  3. ncbi request reprint Pathogenesis of viral hemorrhagic fever
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Immunol 17:399-403. 2005
  4. ncbi request reprint Filoviruses: recent advances and future challenges
    Mike Bray
    NIAID NIH, Biodefense Clinical Research Branch, 6700A Rockledge Drive, Room 5128, Bethesda, MD 20892, USA
    Expert Rev Anti Infect Ther 4:917-21. 2006
  5. pmc Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections
    Janie Parrino
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Emerg Infect Dis 13:191-8. 2007
  6. pmc Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever
    Brian B Gowen
    Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA
    Virol J 7:240. 2010
  7. ncbi request reprint Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Biochem Cell Biol 37:1560-6. 2005
  8. ncbi request reprint Filovirus research: knowledge expands to meet a growing threat
    Mike Bray
    Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 196:S438-43. 2007
  9. ncbi request reprint Pathogenesis and potential antiviral therapy of complications of smallpox vaccination
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Antiviral Res 58:101-14. 2003
  10. ncbi request reprint Progressive vaccinia
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Infect Dis 36:766-74. 2003

Detail Information

Publications50

  1. ncbi request reprint Experimental therapy of filovirus infections
    Mike Bray
    Department of Viral Therapeutics, Virology Division, US Army Medical Research Institute of Infectious Diseases USAMRIID, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Antiviral Res 54:1-17. 2002
  2. ncbi request reprint Looking back at smallpox
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 38:882-9. 2004
    ..Some patients with high levels of circulating virus developed hemorrhagic disease resembling septic shock. Continued study of virus-host interactions is needed to defend against genetically modified agents...
  3. ncbi request reprint Pathogenesis of viral hemorrhagic fever
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Immunol 17:399-403. 2005
    ..The synthesis of tissue factor by infected cells can also trigger coagulation. Failure of adaptive immunity through impaired dendritic cell function and lymphocyte apoptosis can have a crucial role in fatal infection...
  4. ncbi request reprint Filoviruses: recent advances and future challenges
    Mike Bray
    NIAID NIH, Biodefense Clinical Research Branch, 6700A Rockledge Drive, Room 5128, Bethesda, MD 20892, USA
    Expert Rev Anti Infect Ther 4:917-21. 2006
  5. pmc Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections
    Janie Parrino
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Emerg Infect Dis 13:191-8. 2007
    ..These findings suggest that interventions aimed at reducing the extent of immune cell apoptosis could improve outcomes for a variety of severe human infections, including those caused by emerging pathogens and bioterrorism agents...
  6. pmc Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever
    Brian B Gowen
    Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA
    Virol J 7:240. 2010
    ..Although rodent models have been used to evaluate treatments for increased vascular permeability (VP) in bacterial sepsis, such studies have not been performed for VHF...
  7. ncbi request reprint Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Biochem Cell Biol 37:1560-6. 2005
    ..These findings suggest that modifying host responses would be an effective therapeutic strategy, and treatment of infected macaques with a tissue-factor inhibitor reduced both inflammation and viral replication and improved survival...
  8. ncbi request reprint Filovirus research: knowledge expands to meet a growing threat
    Mike Bray
    Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 196:S438-43. 2007
  9. ncbi request reprint Pathogenesis and potential antiviral therapy of complications of smallpox vaccination
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Antiviral Res 58:101-14. 2003
    ..Both laboratory research and clinical studies are needed to help prevent serious complications in any major vaccination campaign...
  10. ncbi request reprint Progressive vaccinia
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Infect Dis 36:766-74. 2003
    ..Almost all cases were treated with vaccinia immune globulin, but its efficacy has never been tested in a placebo-controlled trial. Further research is needed to develop effective forms of therapy...
  11. ncbi request reprint Defense against filoviruses used as biological weapons
    Mike Bray
    Medical Officer, Biodefense Clinical Research Branch, OCR OD NIAID NIH, 6700A Rockledge Drive, Room 5132, Bethesda, MD 20892, USA
    Antiviral Res 57:53-60. 2003
    ..Terrorists might have great difficulty acquiring a filovirus for use as a weapon, but my attempt to do so because of the agents' ability to inspire fear. Accurate information is the best tool to prevent panic in the event of an attack...
  12. doi request reprint Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes
    Mike Bray
    Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD 21702, USA
    Antiviral Res 88:129-42. 2010
    ....
  13. pmc Molecular imaging of influenza and other emerging respiratory viral infections
    Mike Bray
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1348-59. 2011
    ..Molecular techniques might also be used to identify novel biomarkers of disease progression and to evaluate new therapies...
  14. doi request reprint Highly pathogenic RNA viral infections: challenges for antiviral research
    Mike Bray
    Integrated Research Facility, Division of Clinical Research National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 5128, 6700A Rockledge Drive, Bethesda, MD 20892, USA
    Antiviral Res 78:1-8. 2008
    ....
  15. ncbi request reprint Antiviral prophylaxis of smallpox
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Antimicrob Chemother 54:1-5. 2004
    ..Both approaches may avoid the nephrotoxicity that occasionally results from intravenous cidofovir therapy...
  16. ncbi request reprint Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge
    Yvette Edghill-Smith
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infect Dis 191:372-81. 2005
    ..Thus, vaccination strategies that bypass CD4(+) cell help are needed to elicit IgG antibodies with high affinity and adequate tissue distribution and to restore protection against smallpox in severely immunocompromised individuals...
  17. ncbi request reprint Subunit recombinant vaccine protects against monkeypox
    Jean Michel Heraud
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 177:2552-64. 2006
    ..Their identification may guide future efforts to develop simpler, safer, and more effective vaccines for monkeypox and smallpox...
  18. pmc Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge
    Chad J Roy
    Department of Aerobiology and Product Evaluation, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
    Antimicrob Agents Chemother 47:2933-7. 2003
    ..All or nearly all mice that were treated once by aerosol, from 2 days before to 2 days after challenge, survived intranasal infection, whereas all placebo-treated animals died...
  19. ncbi request reprint A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus
    Jason Paragas
    Virology Division, United States Army Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Antiviral Res 62:21-5. 2004
    ..Development of this simple and reliable assay will potentially allow high-throughput screening for discovering additional antiviral drugs to combat this important public health threat...
  20. ncbi request reprint Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus
    Yvette Edghill-Smith
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, 41 D804, Bethesda, Maryland 20892, USA
    Nat Med 11:740-7. 2005
    ..Thus, vaccines able to induce long-lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax)...
  21. ncbi request reprint Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus
    Jenny Riemenschneider
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 21:4071-80. 2003
    ....
  22. ncbi request reprint Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques
    Yvette Edghill-Smith
    Laboratory of Receptor Biology and Gene Expression, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 5055, USA
    J Infect Dis 188:1181-91. 2003
    ....
  23. ncbi request reprint Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus
    Laura G Barrientos
    Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Antiviral Res 58:47-56. 2003
    ..Overall, these studies broaden the range of viruses known to be inhibited by CV-N, and further implicate carbohydrate moieties on viral surface proteins as common viral molecular targets for this novel protein...
  24. doi request reprint Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein
    Arthur Goff
    Virology Division, Viral Therapeutics Branch, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Arch Virol 156:1877-81. 2011
    ..MPXV-GFP could improve the quantitative assessment of antiviral therapy and vaccine efficacy...
  25. ncbi request reprint Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections
    Robert O Baker
    Department of Viral Therapeutics, Virology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Antiviral Res 57:13-23. 2003
    ..Preliminary data indicate that nearly all isolates appear to have similar drug sensitivities. These findings are currently being verified and expanded...
  26. ncbi request reprint Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir
    Mike Bray
    Virology Division, United States Army Medical Research Institute of Infectious Diseases USAMRIID, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Antiviral Res 54:129-42. 2002
    ..The results suggest that aerosolized cidofovir would be effective for prophylaxis or early post-exposure therapy of human smallpox or monkeypox virus infection...
  27. ncbi request reprint Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection
    Siddhartha Mahanty
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Virology 312:415-24. 2003
    ..In this model of Ebola virus infection, the nonlethal sc route of infection is associated with an attenuated inflammatory response and early production of antiviral cytokines, particularly IFN-alpha, as compared with lethal ip infection...
  28. ncbi request reprint Potential applications of conventional and molecular imaging to biodefense research
    King Li
    Department of Radiology, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Infect Dis 40:1471-80. 2005
    ....
  29. pmc Computer-assisted detection of infectious lung diseases: a review
    Ulas Bagci
    Center for Infectious Disease Imaging, Department of Radiology and Imaging Sciences, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Comput Med Imaging Graph 36:72-84. 2012
    ..In this paper, we review the most common radiographic and CT features of respiratory tract infections, discuss the challenges of defining and measuring these disorders with CAD, and propose some strategies to address these challenges...
  30. doi request reprint Basic clinical and laboratory features of filoviral hemorrhagic fever
    Mark G Kortepeter
    Department of Preventive Medicine, Infectious Disease Clinical Research Program, Uniformed Services University of Health Sciences, Bethesda, Maryland 20814 5119, USA
    J Infect Dis 204:S810-6. 2011
    ..By identifying key unanswered questions and gaps in clinical data, it will help guide clinical research in future outbreaks...
  31. ncbi request reprint 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice
    Mike Bray
    Virology Division, Department of Viral Therapeutics, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Antiviral Res 55:151-9. 2002
    ..3-deazaneplanocin A appears to reverse such suppression, restricting viral dissemination. Further development should focus on identifying adenosine analogues that produce a similar effect in Ebola virus-infected primates...
  32. doi request reprint Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways
    Natarajan Ayithan
    1 Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
    J Interferon Cytokine Res 34:79-89. 2014
    ..These results indicate that eVLP stimulate early innate immune responses through TLR and type I IFN signaling pathways to protect the host from EBOV infection. ..
  33. doi request reprint Eczema vaccinatum
    Jennifer L Reed
    Laboratory of Plasma Derivatives, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20892, USA
    Clin Infect Dis 54:832-40. 2012
    ..We conclude by considering how its occurrence might be minimized in the event of a return to universal vaccination...
  34. doi request reprint Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus
    Mark G Kortepeter
    Department of Preventive Medicine, Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, MD 20814, USA
    J Infect Dis 204:S1000-10. 2011
    ..This is the first report of continuous physiologic monitoring in filovirus-infected nonhuman primates and the first to attempt cardiovascular support with intravenous fluids...
  35. pmc The role of radiology in influenza: novel H1N1 and lessons learned from the 1918 pandemic
    Daniel J Mollura
    Radiology and Imaging Sciences, National Institutes of Health, Clinical Center, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Am Coll Radiol 7:690-7. 2010
    ..The broad range of current imaging capabilities will make it possible to study influenza at the cellular level, in animal models, and in human clinical trials to elucidate the pathogenesis of severe illness and improve clinical outcomes...
  36. pmc Imaging findings in a fatal case of pandemic swine-origin influenza A (H1N1)
    Daniel J Mollura
    Department of Radiology and Imaging Sciences, National Institutes of Health, Clinical Center, Bethesda, MD, USA
    AJR Am J Roentgenol 193:1500-3. 2009
    ..We describe the radiographic and CT findings in a fatal S-OIV infection...
  37. pmc Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery
    Tsung Hsien Chang
    Program in Genomics of Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 5:e1000493. 2009
    ....
  38. ncbi request reprint Andes virus infection of cynomolgus macaques
    Anita K McElroy
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
    J Infect Dis 186:1706-12. 2002
    ..This study is the first demonstration of infection of nonhuman primates by an HPS-causing virus...
  39. ncbi request reprint Pathogenesis of filoviral haemorrhagic fevers
    Siddhartha Mahanty
    Malaria Vaccine Development Unit, at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Lancet Infect Dis 4:487-98. 2004
    ..Recent studies in non-human primates have shown that blocking of certain host responses, such as the coagulation cascade, can result in reduced viral replication and improved host survival...
  40. pmc Current and future antiviral therapy of severe seasonal and avian influenza
    John Beigel
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Antiviral Res 78:91-102. 2008
    ....
  41. pmc Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents
    Peter Jahrling
    Integrated Research Facility, National Institute of Allergy and Infectious Diseases, Frederick, Maryland 21702, USA
    Biosecur Bioterror 7:135-43. 2009
    ..Instead, laboratory workers accidentally exposed to pathogens should be cared for in hospital isolation suites staffed by highly trained professionals following strict infection control procedures...
  42. ncbi request reprint Henry Kempe and the birth of vaccinia immune globulin
    Mike Bray
    Clin Infect Dis 39:767-9. 2004
  43. pmc Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses
    Donald F Smee
    Institute for Antiviral Research, Utah State University, Logan, Utah 84322 5600, USA
    Antimicrob Agents Chemother 46:1329-35. 2002
    ..Studies will need to be conducted with cidofovir-resistant monkeypox virus in monkeys to further support these hypotheses...
  44. ncbi request reprint Ebola hemorrhagic fever and septic shock
    Mike Bray
    J Infect Dis 188:1613-7. 2003
  45. ncbi request reprint Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient
    Daniel G Bausch
    Tulane School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA
    J Infect Dis 196:S136-41. 2007
    ..A summary of the opportunities for and challenges to improving treatment of filovirus hemorrhagic fevers is presented here...
  46. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein...
  47. pmc Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells
    Mangala Rao
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
    J Virol 76:9176-85. 2002
    ..Although immunization of the monkeys with L(EV)-induced virus-neutralizing antibodies against EBO-Z caused a slight delay in the onset of illness, it did not prevent death...
  48. ncbi request reprint New data in a 200-year investigation
    Mike Bray
    Clin Infect Dis 38:90-1. 2004
  49. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
    ....
  50. pmc Molecular determinants of Ebola virus virulence in mice
    Hideki Ebihara
    Institute of Medical Science, University of Tokyo, Tokyo, Japan
    PLoS Pathog 2:e73. 2006
    ..These findings suggest a critical role for overcoming the interferon-induced antiviral state in the pathogenicity of EBOV and offer new insights into the pathogenesis of EBOV infection...